- Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.
- Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids.
- Key opinion leaders’ discussion highlights new data and is available on demand.
RBC Capital Maintains Outperform on Nutanix, Raises Price Target to $33
RBC Capital analyst Matthew Hedberg maintains Nutanix (NASDAQ:NTNX) with a Outperform and raises the price target from $31 to $33.
